• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by EUDA Health Holdings Limited

    8/26/25 4:30:02 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care
    Get the next $EUDA alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of August 2025

     

    Commission File Number: 001-40678

     

    EUDA Health Holdings Limited

    (Exact Name of Registrant as Specified in its Charter)

     

    1 Pemimpin Drive #12-06

    One Pemimpin Singapore 576151

    (Address of Principal Executive Offices and Zip Code)

    Registrant’s telephone number, including area code: +65 6268 6821

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

     

     

     

     
     

     

    Other Events.

     

    On August 26, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.

     

    Exhibits

     

    99.1 Press release dated August 26, 2025.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

    Dated: August 26, 2025    
       
      EUDA Health Holdings Limited
         
      By: /s/ Vivian Tay
      Name: Vivian Tay
      Title: Interim Chief Financial Officer

     

     

     

     

    Get the next $EUDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EUDA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EUDA
    SEC Filings

    View All

    SEC Form 6-K filed by EUDA Health Holdings Limited

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    9/4/25 4:30:11 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by EUDA Health Holdings Limited

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    8/28/25 4:30:02 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by EUDA Health Holdings Limited

    6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

    8/26/25 4:30:02 PM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    $EUDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio

    SINGAPORE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" or the "Company") (NASDAQ:EUDA), a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced that it has secured distribution rights for T-cell immunotherapies in Malaysia developed by Shenzhen Inno Immune Co. Ltd. ("Shenzhen Inno"), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in China. These T-cell immunotherapies are designed to restore and rebuild the body's natural defenses. This marks EUDA's second major step into advanced cell therapy this year, following its April 2025 dist

    9/4/25 8:00:00 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd

    SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the "LOI") to potentially acquire Chemokine Pte Ltd ("Chemokine"). EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty (120) days during which it shall not engage in any discussions with any other entity relating to any transaction similar to this potential acquisition. Chemokine is a Singapore ba

    8/28/25 8:00:00 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement

    SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the "Supplement") from Chemokine Pte. Ltd. ("Chemokine"), a Singapore-based biotech company focused on molecular supplements and gene modulating formulations. EUDA and its subsidiaries will market and sell the Supplement under the brand name, Euda Helixé, initially in Singapore, Malaysia, and Chi

    8/26/25 8:00:00 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    $EUDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by EUDA Health Holdings Limited

    SC 13G - EUDA Health Holdings Ltd (0001847846) (Subject)

    3/27/24 7:35:31 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care